Importantly, nintedanib was effective at reducing the rate of decline in FVC both when used as monotherapy and when used as add-on to a stable dose of mycophenolate [43], and had a consistent effect across subgroups of patients with SSc-ILD, including those with limited versus diffuse cutaneous SSc and ATA-negative versus ATA-positive patients [41••, 44]. The gene discussed is ATM; the disease is systemic sclerosis.